- Home
- LSH vs INDP Comparison
LSH vs INDP Comparison
Compare LSH & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSH
- INDP
- Stock Information
- Founded
- LSH 2018
- INDP 2000
- Country
- LSH United States
- INDP United States
- Employees
- LSH N/A
- INDP N/A
- Industry
- LSH
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- LSH
- INDP Health Care
- Exchange
- LSH NYSE
- INDP Nasdaq
- Market Cap
- LSH 6.6M
- INDP 6.0M
- IPO Year
- LSH 2024
- INDP N/A
- Fundamental
- Price
- LSH $0.92
- INDP $12.00
- Analyst Decision
- LSH
- INDP Strong Buy
- Analyst Count
- LSH 0
- INDP 2
- Target Price
- LSH N/A
- INDP $238.00
- AVG Volume (30 Days)
- LSH 14.2K
- INDP 698.6K
- Earning Date
- LSH 08-01-2025
- INDP 08-11-2025
- Dividend Yield
- LSH N/A
- INDP N/A
- EPS Growth
- LSH N/A
- INDP N/A
- EPS
- LSH N/A
- INDP N/A
- Revenue
- LSH $16,270,095.00
- INDP N/A
- Revenue This Year
- LSH N/A
- INDP N/A
- Revenue Next Year
- LSH N/A
- INDP N/A
- P/E Ratio
- LSH N/A
- INDP N/A
- Revenue Growth
- LSH N/A
- INDP N/A
- 52 Week Low
- LSH $0.82
- INDP $7.56
- 52 Week High
- LSH $4.34
- INDP $66.64
- Technical
- Relative Strength Index (RSI)
- LSH N/A
- INDP 53.68
- Support Level
- LSH N/A
- INDP $9.45
- Resistance Level
- LSH N/A
- INDP $13.40
- Average True Range (ATR)
- LSH 0.00
- INDP 2.17
- MACD
- LSH 0.00
- INDP 0.20
- Stochastic Oscillator
- LSH 0.00
- INDP 29.39
About LSH LAKESIDE HOLDING LTD
Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.